Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | thromboxane A synthase 1 (platelet) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | cytochrome P450, putative | thromboxane A synthase 1 (platelet) | 534 aa | 498 aa | 21.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | retinoic acid receptor rxr beta a | 0.0686 | 0.1024 | 1 |
Loa Loa (eye worm) | nuclear receptor nhr-7B | 0.4456 | 0.9707 | 1 |
Brugia malayi | nuclear hormone receptor | 0.4456 | 0.9707 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.4343 | 0.9445 | 0.973 |
Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.0558 | 0.0731 | 1 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0686 | 0.1024 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | 0 mg kg-1 | Thromboxane synthase inhibitor (TxSI) activity was assessed by ex vivo inhibition of serum TXB2 production in rat after oral administration; NT=Not tested | ChEMBL. | 11858999 |
ED50 (functional) | > 1 mg kg-1 | Thromboxane synthase inhibitor (TxSI) activity assessed by ex vivo inhibition of serum TXB2 production in rat after Intravenous administration | ChEMBL. | 11858999 |
ED50 (functional) | > 1 mg kg-1 | Thromboxane synthase inhibitor (TxSI) activity assessed by ex vivo inhibition of serum TXB2 production in rat after Intravenous administration | ChEMBL. | 11858999 |
ED50 (functional) | = 4.2 mg kg-1 | Antagonism of Platelet activating factor (PAF)in mice after Intravenous administration, assayed by PAF-induced death | ChEMBL. | 11858999 |
ED50 (functional) | = 4.2 mg kg-1 | Antagonism of Platelet activating factor (PAF)in mice after Intravenous administration, assayed by PAF-induced death | ChEMBL. | 11858999 |
ED50 (functional) | > 10 mg kg-1 | Antagonism of Platelet activating factor (PAF) activity in mice after oral administration, assayed by PAF-induced death | ChEMBL. | 11858999 |
ED50 (functional) | > 10 mg kg-1 | Antagonism of Platelet activating factor (PAF) activity in mice after oral administration, assayed by PAF-induced death | ChEMBL. | 11858999 |
IC50 (functional) | = 0.069 uM | In vitro inhibition of thromboxane synthase (TXA2) in human platelet microsomes [reduced formation of TXB2 from prostaglandin H2(PGH2)] | ChEMBL. | 11858999 |
IC50 (functional) | = 0.069 uM | In vitro inhibition of thromboxane synthase (TXA2) in human platelet microsomes [reduced formation of TXB2 from prostaglandin H2(PGH2)] | ChEMBL. | 11858999 |
IC50 (functional) | = 0.085 uM | Inhibition of Platelet activating factor (PAF)- induced platelet aggregation in rabbit platelet rich plasma (PRP) | ChEMBL. | 11858999 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.